CD Formulation's laboratories have successfully developed a series of innovative and diverse technology platforms based on years of experience and high-end technology in small molecule targeting research. We provide modules for target-specific binding, including GalNAc, antibody-drug couples, peptide-drug couples, etc. We offer services such as modification and development to efficiently provide solutions for our clients' projects and to better develop their drugs in terms of delivery.
As an extremely important part of the delivery system, the following modules can be used to provide the feasibility of therapeutic targets for the development of potential therapies. These modules can be used to find and demonstrate diagnostic biomarkers that can be physically/chemically coupled to a carrier for the development of drug delivery systems.
GalNAc technology is a targeted delivery technology based on specific chemical modifications, mainly for small nucleic acid drugs. The principle is that GalNAc has a high affinity for sialic acid glycoprotein (ASGPR), which is predominantly expressed on the surface of liver parenchymal cells. The advantages of GalNAc delivery include subcutaneous administration, long duration of action, hepatic targeting specificity and low toxicity.
Antibody-drug coupling (ADC) is a targeted drug delivery system in which specific antibodies are used to target specific cells and cytotoxic substances are coupled to them via linker molecules. Antibody-drug coupling technology uses monoclonal antibodies or other biological agents to deliver highly active drug components to target cells. In the coupled form, the highly active drug component can exhibit higher selective therapeutic activity, protect non-target cells from many toxic effects, and improve safety.
Peptide-drug couplings (PDCs) are targeted therapeutic agents that function similarly to ADC. Peptides are an important type of molecule for biocoupling derivatization. Peptide-drug couples hold promise for therapeutic drug delivery by offering the unique advantage of increasing the therapeutic potential of a drug. Both linear and cyclic peptides have been explored as transport components due to their ease of synthesis, structural simplicity and low potential for adverse immunogenicity.
CD Formulation offers customized services based on multivalent targeting strategies that can provide sufficient affinity and enhanced effective association to overcome the low affinity of each monovalent module. Among the modification services we offer are chemical modifications, the advantages of which include altered affinity, charge, hydrophobicity, stability, solubility, etc. Equipped with our well-established drug delivery systems, we can offer individual targeting technologies or different kinds of cargo-drug conjugates for specific diseases, cancer protein biomarkers and subcellular organelles.
CD Formulation provides integrated and innovative solutions from strategy to implementation to help you increase your opportunities and address your challenges. Through our in-depth experience in many different industries, including consumer and technology, we bring innovative solutions and cross-industry best practices to drug development. If you have any requests for our services, please contact us by phone or email and one of our colleagues will get back to you within three business days.